Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.After a disappointing phase II trial, Finnish company Orion Pharma has elected not to take its oral formulation of its heart drug levosimendan into phase III development. Orion said that the study results were "not sufficient" to begin phase III clinical trials.
Subscribe to our email newsletter
The study evaluated treatment of about 300 patients who had severe chronic heart failure despite traditional treatment. They were studied in three groups, two of which were treated with different doses of levosimendan while one of the groups received standard medication.
The primary endpoints of the study included an assessment of symptoms, the need for hospitalization, and mortality.
The results did not show clear enough significance to meet the primary endpoints.